Advice

in the absence of a submission from the holder of the marketing authorisation:

chenodeoxycholic acid (Chenodeoxycholic acid Leadiant®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice355KB (PDF)

Download

Medicine details

Medicine name:
chenodeoxycholic acid (Chenodeoxycholic acid Leadiant)
SMC ID:
SMC2190
Indication:
The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.
Pharmaceutical company
Leadiant Biosciences
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
13 May 2019